Is the WHO's "biological qualifier" really needed?
This article was originally published in Scrip
Executive Summary
The World Health Organization has launched a public consultation on its compromise proposal for a "biological qualifier" (BQ) that could be assigned to all biological substances with an international non-proprietary name (INN). The BQ, which would identify the manufacturer and manufacturing site of the active substance, would apply to all substances, regardless of whether the branded product was an originator or a biosimilar drug.
You may also be interested in...
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.